Table 1.

Patient characteristics.

	Hypogammaglobulinemia (n = 89)		Normal immunoglobulin level (n = 36)	p-value
	IVIG (n = 56)	Non-IVIG (n = 33)
Age, median (range)	77 (70–90)	79 (70–85)	77.5 (70–86)	0.965
≥80, n (%)	16 (28.6)	13 (39.4)	12 (33.3%)
Sex				0.534
Male, n (%)	30 (53.6)	16 (48.5)	24 (66.7)
Elevated LDH, n (%)	35 (62.5)	23 (69.7)	22 (61.1%)	0.723
ECOG, n (%)				0.192
0–1	31 (55.4)	11 (33.3)	20 (55.6)
2–3	25 (44.6)	22 (66.7)	16 (44.4)
EN involvement, n (%)				0.053
0	26 (46.4)	6 (18.2)	13 (36.1)
1	21 (37.5)	15 (45.5)	10 (27.8)
≥2	9 (16.1)	12 (36.4)	13 (36.1)
Ann Arbor stage, n (%)				0.453
1	4 (7.1)	5 (15.2)	4 (11.1)
2	19 (33.9)	10 (30.3)	13 (36.1)
3	13 (23.2)	3 (9.1)	9 (25.0)
4	20 (35.7)	15 (45.5)	10 (27.8)
IPI				0.221
1	12 (21.4)	11 (33.3)	3 (8.3)
2	11 (19.6)	3 (9.1)	6 (16.7)
3	11 (19.6)	8 (24.2)	15 (41.7)
4	16 (28.6)	6 (18.2)	9 (25.0)
5	6 (10.7)	5 (15.2)	3 (8.3)
No. of COVID-19 vaccinations, n (%)				0.684
none	31 (55.4)	18 (54.5)	21 (58.3)
1	16 (28.6)	8 (24.2)	9 (25.0)
2	9 (16.1)	7 (21.2)	6 (16.7)
*Prior COVID-19 infection, n (%)	5 (8.9)	1 (3.0)	3 (8.3)	0.555
Prophylactic antibiotics, n (%)	54 (96.4)	33 (100.0)	36 (100.0)	0.286
Prophylactic antiviral agent, n (%)	25 (44.6)	21 (63.6)	15 (41.7)	0.545
Prophylactic anti-PCP agent, n (%)	23 (41.1)	25 (75.8)	21 (58.3)	0.116
Prophylactic antifungal agent, n (%)	50 (89.3)	30 (90.9)	32 (88.9)	0.278

COVID-19, coronavirus disease 2019; ECOG, Eastern Cooperative Oncology Group; EN, extra nodal; IPI, International Prognostic Index; IVIG, intravenous immunoglobulin; LDH, lactate dehydrogenase; PCP, pneumocystis pneumonia.

*History of past COVID-19 infection before diagnosis of DLBCL.